Improvement in hematopoiesis after iron chelation therapy with deferasirox in patients with aplastic anemia

Acta Haematologica

Volumn 129, Issue 2, 2013, Pages 72-77

  Lee, Sung Eun ^a   Yahng, Seung Ah ^a   Cho, Byung Sik ^a   Eom, Ki Sung ^a   Kim, Yoo Jin ^a   Lee, Seok ^a   Min, Chang Ki ^a   Kim, Hee Je ^a   Cho, Seok Goo ^a   Kim, Dong Wook ^a   Min, Woo Sung ^a   Park, Chong Won ^a   Lee, Jong Wook ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Aplastic anemia; Deferasirox; Hematopoiesis; Iron chelation therapy; Transfusion dependence

Indexed keywords

CYCLOSPORIN; DEFERASIROX; FERRITIN; HEMOGLOBIN; HLA ANTIGEN; METHYLPREDNISOLONE; THYMOCYTE ANTIBODY; BENZOIC ACID DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; IRON; IRON CHELATING AGENT; TRIAZOLE DERIVATIVE;

ADULT; APLASTIC ANEMIA; ARTICLE; BLOOD SMEAR; BONE MARROW BIOPSY; CASE REPORT; CHELATION THERAPY; DRUG TREATMENT FAILURE; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITIN BLOOD LEVEL; HEMATOPOIESIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IRON CHELATION; IRON OVERLOAD; LEUKOCYTE COUNT; MALE; NEUTROPHIL COUNT; PANCYTOPENIA; PRIORITY JOURNAL; RETICULOCYTE COUNT; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; CHROMOSOME FRAGILITY; CONTINUOUS INFUSION; CYTOGENETICS; HEPATITIS B; HEPATOSPLENOMEGALY; HUMAN TISSUE; VAGINA BLEEDING; YOUNG ADULT; BLOOD; BLOOD TRANSFUSION; DRUG EFFECT;

ADULT; ANEMIA, APLASTIC; BENZOATES; BLOOD TRANSFUSION; CHELATION THERAPY; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITINS; HEMATOPOIESIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; PLATELET TRANSFUSION; TRIAZOLES;

MLCS; MLOWN;

EID: 84868686185     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000342772     Document Type: Article

References (27)

1. Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C, Di Gregorio F, Burattini MG, Terzoli S: Survival and causes of death in thalassaemia major. Lancet 1989; 2: 27-30. (Pubitemid 19158169)
2. Takatoku M, Uchiyama T, Okamoto S, Kanakura Y, Sawada K, Tomonaga M, Nakao S, Nakahata T, Harada M, Murate T, Ozawa K: Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol 2007; 78: 487-494. (Pubitemid 46753591)
3. Schafer AI, Cheron RG, Dluhy R, Cooper B, Gleason RE, Soeldner JS, Bunn HF: Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med 1981; 304: 319-324. (Pubitemid 11179024)
4. Cappellini MD, Taher A: Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload. Expert Opin Pharmacother 2008; 9: 2391-2402.
5. Koh KN, Park M, Kim BE, Im HJ, Seo JJ: Restoration of hematopoiesis after iron chelation therapy with deferasirox in 2 children with severe aplastic anemia. J Pediatr Hematol Oncol 2010; 32: 611-614.
6. Lee JW, Jang PS, Chung NG, Cho B, Jeong DC, Kim HK: Iron chelation therapy with deferasirox results in recovery of hematopoiesis in a child with aplastic anemia. Pediatr Hematol Oncol 2011; 28: 718-720.
7. Park SJ, Han CW: Complete hematopoietic recovery after continuous iron chelation therapy in a patient with severe aplastic anemia with secondary hemochromatosis. J Korean Med Sci 2008; 23: 320-323.
8. Delea TE, Hagiwara M, Phatak PD: Retrospective study of the association between transfusion frequency and potential complications of iron overload in patients with myelodysplastic syndrome and other acquired hematopoietic disorders. Curr Med Res Opin 2009; 25: 139-147.
9. Lee JW: Iron chelation therapy in the myelodysplastic syndromes and aplastic anemia: a review of experience in South Korea. Int J Hematol 2008; 88: 16-23.
10. Wimazal F, Nosslinger T, Baumgartner C, Sperr WR, Pfeilstocker M, Valent P: Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes. Eur J Clin Invest 2009; 39: 406-411.
11. Wood JC, Kang BP, Thompson A, Giardina P, Harmatz P, Glynos T, Paley C, Coates TD: The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood 2010; 116: 537-543.
12. Lee JW, Yoon SS, Shen ZX, Ganser A, Hsu HC, Habr D, Domokos G, Roubert B, Porter JB: Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial. Blood 2010; 116: 2448-2454.
13. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW: Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994; 331: 567-573. (Pubitemid 24265698)
14. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR: Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994; 331: 574-578. (Pubitemid 24265699)
15. Rose C, Brechignac S, Vassilief D, Pascal L, Stamatoullas A, Guerci A, Larbaa D, Dreyfus F, Beyne-Rauzy O, Chaury MP, Roy L, Cheze S, Morel P, Fenaux P: Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients A multicenter study by the GFM (Groupe Francophone des Myelodysplasies). Leuk Res 2010; 34: 864-870.
16. Guariglia R, Martorelli MC, Villani O, Pietrantuono G, Mansueto G, D'Auria F, Grieco V, Bianchino G, Lerose R, Bochicchio GB, Musto P: Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review. Leuk Res 2011; 35: 566-570.
17. Messa E, Cilloni D, Messa F, Arruga F, Roetto A, Saglio G: Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta Haematol 2008; 120: 70-74.
18. Capalbo S, Spinosa G, Franzese MG, Palumbo G: Early deferasirox treatment in a patient with myelodysplastic syndrome results in a long-term reduction in transfusion requirements. Acta Haematol 2009; 121: 19-20.
19. Oliva EN, Ronco F, Marino A, Alati C, Pratico G, Nobile F: Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients. Transfusion 2010; 50: 1568-1570.
20. Nishiuchi T, Okutani Y, Fujita T, Yoshida K, Ohnishi H, Haba R: Effect of iron chelator deferasirox on chronic anemia and thrombocytopenia in a transfusion-dependent patient with myelodysplastic syndrome. Int J Hematol 2010; 91: 333-335.
21. Breccia M, Loglisci G, Salaroli A, Cannella L, Santopietro M, Alimena G: Deferasirox treatment interruption in a transfusion-requiring myelodysplastic patient led to loss of erythroid response. Acta Haematol 2010; 124: 46-48.
22. Jensen PD, Heickendorff L, Pedersen B, Bendix-Hansen K, Jensen FT, Christensen T, Boesen AM, Ellegaard J: The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 1996; 94: 288-299. (Pubitemid 26247987)
23. Vreugdenhil G, Smeets M, Feelders RA, van Eijk HG: Iron chelators may enhance erythropoiesis by increasing iron delivery to haematopoietic tissue and erythropoietin response in iron-loading anaemia. Acta Haematol 1993; 89: 57-60. (Pubitemid 23193193)
24. Kontoghiorghes GJ, May A: Uptake and intracellular distribution of iron from transferrin and chelators in erythroid cells. Biol Met 1990; 3: 183-187.
25. Louache F, Testa U, Pelicci P, Thomopoulos P, Titeux M, Rochant H: Regulation of transferrin receptors in human hematopoietic cell lines. J Biol Chem 1984; 259: 11576-11582. (Pubitemid 14010050)
26. Wang GL, Semenza GL: Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood 1993; 82: 3610-3615. (Pubitemid 24006041)
27. Taoka K, Kumano K, Nakamura F, Hosoi M, Goyama S, Imai Y, Hangaishi A, Kurokawa M: The effect of iron overload and chelation on erythroid differentiation. Int J Hematol 2012; 95: 149-159